01.09.2023 | Tracker

Top 50 Pharma Tracker: Novo Nordisk’s semaglutide trial gets praise from HCPs

By Aman Jandu

Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.

The Top 50 Pharmaceutical Companies mentioned by eHCPs on X

August RankJuly RankCompany
Name
Total
Mentions
Account
Mentions
Account
Retweets
11Pfizer4,1855114
22Moderna2,2101016
34GSK61311713
43Johnson & Johnson48014010
511Novo Nordisk45925126
67AstraZeneca3651339
716Novavax349535
86Otsuka2621161
913Bayer228676
1014Sanofi1976419
119Abbott1821424
1212Roche1684811
1315Merck & Co1661002
1410BioNTech161260
1517BMS1501052
165Lilly1461040
1718Novartis143643
188Gilead Sciences138324
1924Daiichi Sankyo98141
2022AbbVie79382
2133Teva61576
2219Biogen58330
2326Amgen50343
2425Boehringer Ingelheim44282
2429Regeneron44130
2628Organon4300
2735Servier252519
2829Astellas24131
2920Eisai21110
2923Fresenius21135
3132Bausch2040
3221Takeda19160
3337Ipsen1860
3337Viatris1800
3543Vertex11112
3637Sun800
3727Merck KGaA773
3844Incyte620
3937UCB532
3942CSL521
4146CSPC200
4150Chugai210
4331Horizon110
4334Grifols100
4335Menarini110
4344Jazz Pharmaceuticals100
4346Sino100
5041Perrigo000
5046Shanghai000
5050Jiangsu Hengrui000

The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies

The five pharmaceutical companies that were mentioned the most by eHCPs on X (formerly Twitter) in August 2023 were Pfizer, Moderna, GSK, Johnson & Johnson, and Novo Nordisk.

CREATION.co identified 10,144 eHCP mentions of pharmaceutical companies in August 2023.

On 04 August, GSK Nigeria stated that they would be ceasing operations in the country, due to increased competition from local companies and imports from India and China. Many eHCPs expressed their disappointment and sadness to hear the news.

On 08 August, Novo Nordisk shared the results from the SELECT clinical trial testing the efficacy of semaglutide in reducing major adverse cardiovascular events (MACE). The trial appeared to reduce the risk of MACE by 20%, leading to a reduction in risks of heart attacks and strokes. eHCPs were very glad to hear the results, with some congratulating Novo Nordisk on their work.

Other HCPs discussed the effectiveness of semaglutide in obesity reduction and its cardiovascular benefits. Researcher and professor Lykke Sylow was excited by the prospects of what else the drug could achieve, particularly concerning cancer patients.

On 18 August, Moderna shared a press release for their monovalent vaccine for the treatment of circulating COVID-19 variants, detailing the efficacy and improved levels of neutralising antibodies. HCPs called the vaccine’s efficacy “good news”.

The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:

  1. An article referring to the Novavax vaccine for SARS-CoV-2, protecting against viral variants.
  2. An article discussing former deputy medical chief Sir Jonathan Van-Tam joining Moderna as a senior medical consultant.
  3. A press release from Moderna announcing trial data from a new COVID-19 vaccine.

CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology notes:

    • In August 2023, CREATION Pinpoint® identified 10,144 healthcare professional authored posts on X (Twitter) from 3,770 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue). 
    • Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 31 August 2023.
  • Unless otherwise specified, mentions of a company are not limited to its X account(s).
  • In some cases, an X post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
  • Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In August 2023, 193 of these posts mentioned Janssen.

The Top 50 Pharma tracker archive

July 2023: eHCP concern about drug shortages after tornado damages Pfizer facility

Top 50 Table 

Top 50 Insights

June 2023: eHCPs approve of new pharma trial data at ASCO 2023

Top 50 Table 

Top 50 Insights

May 2023: eHCPs commend pharma companies for their contributions to local communities

Top 50 Table

Top 50 Insights

April 2023: eHCPs applaud pharma collaborating with one another

Top 50 Table 

Top 50 Insights

March 2023: eHCPs celebrate Eli Lilly for capping the cost of insulin

Top 50 Table 

Top 50 Insights

December 2022: HCPs celebrate the Moderna and Merck combination melanoma vaccine and immunotherapy

Top 50 Table 

Top 50 Insights

November 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines

Top 50 Table 

Top 50 Insights

October 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines

Top 50 Table

Top 50 Insights

September 2022: Top 50 Pharma Tracker: Bivalent vaccine data and new treatments drive HCP conversation

Top 50 Table

Top 50 Insights

August 2022: Top 50 Pharma Tracker: HCPs discuss bivalent vaccine approval in the UK and advances in obesity treatment.

Top 50 Table
Top 50 Insights

July 2022: Top 50 Pharma Tracker: HCPs continue to discuss Moderna’s COVID-19 vaccine but mentions of Pfizer dramatically decrease

Top 50 Table
Top 50 Insights

June 2022: Top 50 Pharma Tracker: HCPs share mixed opinions on COVID-19 vaccines and treatment data

Top 50 Table
Top 50 Insights

May 2022: Top 50 Pharma Tracker: HCPs discuss Pfizer vaccine documents and share opinions on COVID-19 vaccine efficacy.

Top 50 Table
Top 50 Insights

April 2022: HCPs celebrate the success of Lilly’s tirzepatide for obesity and discuss COVID-19 vaccine efficacy

Top 50 Table
Top 50 Insights

March 2022: HCPs compare immune responses of T cell, B cell, and Antibodies to different COVID-19 vaccines.

Top 50 Table
Top 50 Insights

February 2022: HCPs discuss Healthcare inequity and vaccination of under 5 year olds

Top 50 Table
Top 50 Insights

January 2022: HCPs get political when discussing Regeneron’s COVID-19 treatment

Top 50 Table
Top 50 Insights

December 2021: Omicron variant dominates HCP conversation in December 2021

Top 50 Table
Top 50 Insights

November 2021 : HCPs discuss trial data of Pfizer’s COVID-19 booster vaccine and oral treatment

Top 50 Table
Top 50 Insights

October 2021 : Pfizer most discussed company with booster and children’s COVID-19 jabs

Top 50 Table
Top 50 Insights

July 2021: HCPs discuss “booster shot” to decrease the high spread of the Delta variant

Top 50 Table
Top 50 Insights

June 2021: HCPs discuss effectiveness of COVID-19 vaccines against delta strain.

Top 50 Table
Top 50 Insights

May 2021: HCPs discuss accessibility of COVID-19 treatments globally.

Top 50 Table
Top 50 Insights

April 2021: HCPs reassure the public as they discuss COVID-19 vaccine side effects.

Top 50 Table
Top 50 Insights

March 2021: Oxford-AstraZeneca vaccine provokes HCP conversation as they discuss blood clots as a side effect.

Top 50 Table
Top 50 Insights

February 2021: J&J FDA approval of single-dose vaccine stirs HCP conversations

Top 50 Table
Top 50 Insights

January 2021: J&J new vaccine data drives increase in company posts online

Top 50 Table
Top 50 Insights

December 2020: COVID-19 makes up 84% of total conversation

Top 50 Table
Top 50 Insights

November 2020: Vaccine success dwarfs all other conversation.

Top 50 Table
Top 50 Insights

October 2020: Regeneron tops list due to high profile COVID-19 treatment conversation.

Top 50 Table
Top 50 Insights

September 2020: ASTRAZENECA’S VACCINE TRIAL SAFETY DISCUSSED BUT TRANSPARENCY IS CELEBRATED.

Top 50 Table
Top 50 Insights

August 2020: HCPS DISCUSS ASTRAZENECA MORE THAN GILEAD FOR FIRST TIME SINCE PANDEMIC

Top 50 Table
Top 50 Insights

July 2020: COVID-19 CANDIDATES TAKE OVER ALL HCP CONVERSATION

Top 50 Table
Top 50 Insights

June 2020: HCPs respond to COVID-19 treatment options

Top 50 Table
Top 50 Insights

May 2020: HCPs track pharma covid-19 developments online

Top 50 Table
Top 50 Insights

April 2020: HCPS RESPOND TO PHARMA COVID-19 ACTIVITY

Top 50 Table
Top 50 Insights

March 2020: HCPS MENTIONING PHARMA IN RELATION TO COVID-19

Top 50 Table
Top 50 Insights

February 2020: HCPS DISCUSS GILEAD, EISAI AND MERCK & CO’S TRIAL RESULTS

Top 50 Table
Top 50 Insights

January 2020: NEW YEAR BEGINS WITH FAILED TRIALS AND SUCCESSFUL PODCAST LAUNCH

Top 50 Table
Top 50 Insights

December 2019: @NOVARTIS MOST MENTIONED TWITTER ACCOUNT FOR SECOND MONTH

Top 50 Table
Top 50 Insights

November 2019: GILEAD INTO TOP 5 AFTER PRICE DISCREPANCY

Top 50 Table
Top 50 Insights

October 2019: HCPS ENGAGE WITH TOP 50 PHARMA AROUND GOOD AND BAD NEWS

Top 50 Table
Top 50 Insights

September 2019: HCPS ENGAGED MEANINGFULLY WITH TOP 50 PHARMA

Top 50 Table
Top 50 Insights

August 2019: #WHATHCPSTHINK ABOUT THE TOP 50 PHARMA

Top 50 Table
Top 50 Insights

View all articles >

Meet the Author

Aman Jandu

With a background working in IT systems administration, and leveraging a 1st Class degree in Digital Technologies, Aman uses his technical skills to apply a systematic approach to gather data and analyse insights.

Aman loves to Speedcube. While he can currently solve a Rubik’s Cube in around 20 seconds, he is learning how to complete it blindfolded.

Suggested next


13.02.2024 | Article

What eHCPs think about 2024 clinical trials for pharmaceuticals and digital therapeutic tools

An analysis of how HCPs responded to the 11 clinical trials that will shape medicine in 2024

By Alexandra Maria Chatziioannidou

product launch tracker banner

01.09.2021 | Article

HCPs’ conversation dominated by FDA’s Pfizer vaccine approval

Discover which new drug approvals and launches HCPs are talking about

By Jennifer Ayoade

View all articles >